Recursion Pharmaceuticals, Inc. RXRX

RXRX Company Overview

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines using an integrated artificial intelligence–driven drug discovery platform. The company operates at the intersection of biotechnology, machine learning, and automation, aiming to industrialize drug discovery by systematically mapping biology at scale. Its core strategy is to identify novel therapeutic candidates more efficiently than traditional approaches by combining high-throughput experimental biology with advanced computational models.

The company’s primary revenue drivers currently include drug discovery and development programs, strategic partnerships, and collaboration agreements with large pharmaceutical companies. Recursion primarily targets diseases with high unmet medical need, including rare genetic diseases, oncology, and fibrotic and neurodegenerative disorders. Founded in 2013, the company evolved from an academic-driven biology platform into a publicly traded company following its IPO in 2021, progressively expanding its technology stack, data assets, and clinical pipeline.